Literature DB >> 1261088

Binding of thyroid microsomes by lymphocytes from patients with thyroid disease and normal subjects.

B A Khalid, N T Hamilton, M N Cauchi.   

Abstract

Lymphocytes that could bind 125I-labelled thyroid microsomal membranes (ABL) were present in the peripheral blood of patients with various types of thyroid disease as well as in normal healthy subjects. In patients with anti-thyroid cytoplasmic antibodies the number of ABL was about three times normal (11-21 +/- 0-60 compared with 3-26 +/- 0-18 per 10(4) lymphocytes). In contrast, in patients with thyroid disease without anti-thyroid cytoplasmic antibodies, the number of antigen-binding lymphocytes was not significantly greater than in the normal controls (3-94 +/- 0.14 per 10(4) lymphocytes). The binding of thyroid microsomes by antigen-binding lymphocytes could be blocked by thyroid microsomes but not by thyroid mitochondrial membranes, thyroglobulin or liver microsomes.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1261088      PMCID: PMC1538364     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Incidence of autoantibodies in cancer patients.

Authors:  A E Tannenberg; H K Muller; M N Cauchi; R C Nairn
Journal:  Clin Exp Immunol       Date:  1973-10       Impact factor: 4.330

3.  Isolation of plasma membrane and endoplasmic reticulum fragments from chick embryo fibroblasts.

Authors:  R W Bingham; D C Burke
Journal:  Biochim Biophys Acta       Date:  1972-08-09

4.  Tolerance to an autoantigen-thyroglobulin. Antigen-binding lymphocytes in thymus and blood in health and autoimmune disease.

Authors:  I M Roberts; S Whittingham; I R Mackay
Journal:  Lancet       Date:  1973-10-27       Impact factor: 79.321

5.  Studies on the antigen reacting with the thyroid-stimulating immunoglobulin (LATS) in thyrotoxicosis.

Authors:  N Benhamou-Glynn; D J el-Kabir; I M Roitt; D Doniach
Journal:  Immunology       Date:  1969-02       Impact factor: 7.397

6.  An in vitro reaction between labelled flagellin or haemocyanin and lymphocyte-like cells from normal animals.

Authors:  P Byrt; G L Ada
Journal:  Immunology       Date:  1969-10       Impact factor: 7.397

7.  Inhibition of the long-acting thyroid stimulator (LATS) by soluble thyroid fractions.

Authors:  G Beall; D Doniach; I Roitt; D el Kabir
Journal:  J Lab Clin Med       Date:  1969-06

8.  Lymphocytes binding human thyroglobulin in healthy people and its relevance to tolerance for autoantigens.

Authors:  A D Bankhurst; G Torrigiani; A C Allison
Journal:  Lancet       Date:  1973-02-03       Impact factor: 79.321

9.  Antigen-binding lymphocytes in normal man and guinea pig to human encephalitogenic protein.

Authors:  L L Yung; E Diener; T A McPherson; M A Barton; H A Hyde
Journal:  J Immunol       Date:  1973-05       Impact factor: 5.422

10.  Antigen binding and capping by lymphocytes of genetic nonresponder mice.

Authors:  E K Dunham; E R Unanue; B Benacerraf
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

View more
  3 in total

1.  Immunohistological findings in Hashimoto's thyroiditis, focal lymphocytic thyroiditis and thyroiditis de Quervain. Comparative study.

Authors:  H Knecht; P Saremaslani; C Hedinger
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

2.  Receptors for fluoresceinated human thyroglobulin in peripheral blood lymphocytes.

Authors:  G B Salabè; H Salabè; L Accinni; R Dominici
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

3.  Binding of solubilized human TSH-receptor protein by peripheral blood lymphocytes of patients with Graves' disease.

Authors:  B Wenzel; K W Wenzel; P Kotulla; H Schleusener
Journal:  J Endocrinol Invest       Date:  1981 Apr-Jun       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.